Godmet VG2 Tablet SR is a combination oral antihyperglycemic medication containing Glimepiride (2mg), Metformin (500mg), and Voglibose (0.2mg), designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, attenuating postprandial hyperglycemia. The sustained-release formulation ensures gradual drug release, promoting stable plasma concentrations and improving patient compliance. Godmet VG2 is indicated as an adjunct to diet and exercise to improve glycemic control in patients inadequately controlled on monotherapy or dual therapy. It is essential to monitor blood glucose levels regularly and adjust dosage accordingly to minimize the risk of hypoglycemia and gastrointestinal side effects. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and known hypersensitivity to any component. Caution is advised in patients with cardiovascular disease or lactic acidosis risk factors. This combination therapy offers a multifaceted approach to glycemic management, targeting different pathophysiological aspects of type 2 diabetes.